Who is sponsoring NCT03207568?

NCT03207568 is sponsored by Bolton Medical.

What drugs are being tested in NCT03207568?

Interventions in NCT03207568: Thoracic Endovascular Aortic Repair (TEVAR).

What condition does NCT03207568 study?

NCT03207568 studies Aorta, Thoracic Pathologies, Aortic Aneurysm, Thoracic, Aortic Aneurysm.

Is NCT03207568 still recruiting?

NCT03207568 is currently completed. Last updated 5 July 2017.

Last reviewed 2017-07-05 · How we verify

NCT03207568: RE-GENERATION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)

Completed NA Last updated 5 July 2017

What this trial tests

NA trial testing Thoracic Endovascular Aortic Repair (TEVAR) in Aorta, Thoracic Pathologies in 30 participants. Completed in 30 April 2016.

Timeline

25 October 2014

Primary endpoint
14 April 2016

30 April 2016

Quick facts

Lead sponsor	Bolton Medical
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	25 October 2014
Primary completion	14 April 2016
Estimated completion	30 April 2016

Drugs / interventions tested

Thoracic Endovascular Aortic Repair (TEVAR)

Conditions studied

Aorta, Thoracic Pathologies — all drugs for Aorta, Thoracic Pathologies →
Aortic Aneurysm, Thoracic — all drugs for Aortic Aneurysm, Thoracic →
Aortic Aneurysm — all drugs for Aortic Aneurysm →

Sponsor

Bolton Medical — full company profile →

Who can join

Adults 18 to 85, any sex, with Aorta, Thoracic Pathologies or Aortic Aneurysm, Thoracic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to evaluate the safety and performance of Relay Pro and Relay NBS Pro devices in humans having thoracic aortic pathologies. Clinical results will be used to apply for the CE certification.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hybrid repair versus conventional open repair for thoracic aortic arch aneurysms.
Elhelali A, Hynes N, Devane D, Sultan S, et al · · 2021 · cited 13× · PMID 34085713 · DOI 10.1002/14651858.cd012923.pub2

Verify or expand the search:

Other Bolton Medical trials

Trials by the same sponsor.

NCT07026877 — Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA · NA · recruiting
NCT04697784 — Post-Approval Study of the TREO Abdominal Stent-Graft System · NA · active not recruiting
NCT03214601 — Early Feasibility Study of the RelayBranch Thoracic Stent-Graft System · NA · active not recruiting
NCT03187522 — An European Union (EU) Post-Approval Registry of the TREO® Stent-Graft · NA · terminated
NCT03090230 — Study of the Relay Pro® Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03207568 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bolton Medical
Last refreshed: 5 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03207568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing